David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

FLAT ROCK, MI — Flat Rock Community Schools announced the top 10 graduates in the Flat Rock High School Class of 2025. The ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

“Scholar Rock is at an inflection point as we evolve to a commercial-stage biopharmaceutical company, and our team remains focused on key priorities in preparation for the potential U.S. launch ...

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Biotech stock Scholar Rock (SRRK-1.28%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds.